Patents Assigned to ONO Pharmaceutical Co., Ltd.
  • PHENYL DERIVATIVE
    Publication number: 20190030010
    Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.
    Type: Application
    Filed: October 1, 2018
    Publication date: January 31, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi NAGANAWA, Kensuke KUSUMI, Kazuhiro OTSUKI, Tetsuya SEKIGUCHI, Akito KAKUUCHI, Koji SHINOZAKI, Hiroshi YAMAMOTO, Shigeyuki NONAKA
  • TETRAHYDRONAPHTHALENE DERIVATIVE
    Publication number: 20190031605
    Abstract: A compound represented by general formula (I-1): wherein the symbols are defined in the specification, has a selective S1P5 receptor binding activity and modulates the function of an S1P5 receptor, and can therefore be a therapeutic agent for a S1P5-mediated disease, for example, neurodegenerative diseases such as schizophrenia, Binswanger's disease and the like.
    Type: Application
    Filed: January 27, 2017
    Publication date: January 31, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Yuichi INAGAKI
  • KCNQ2-5 CHANNEL ACTIVATOR
    Publication number: 20180346422
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke WAKAMATSU, Tetsuji SAITO
  • Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma
    Patent number: 10137129
    Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: November 27, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshio Yoshizawa, Ryohei Kozaki
  • DIHYDROINDOLIZINONE DERIVATIVE
    Publication number: 20180334458
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: July 31, 2018
    Publication date: November 22, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • TRICYCLIC SPIRO COMPOUND
    Publication number: 20180319764
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 8, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke TANI, Masaya HIROBE, Satonori HIGUCHI, Kazuhiro FUCHIBE, Ryo OIKAWA, Tohru KOTANI, Hirotsugu TAKANO
  • Phenyl derivative
    Patent number: 10117861
    Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: November 6, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
  • FUSED IMIDAZOLE COMPOUNDS
    Publication number: 20180289718
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Tricyclic spiro compound
    Patent number: 10077247
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 18, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Kousuke Tani, Masaya Hirobe, Satonori Higuchi, Kazuhiro Fuchibe, Ryo Oikawa, Tohru Kotani, Hirotsugu Takano
  • QUINOLINE DERIVATIVE
    Publication number: 20180258072
    Abstract: A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases
    Type: Application
    Filed: May 10, 2018
    Publication date: September 13, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
  • Trk-INHIBITING COMPOUND
    Publication number: 20180256573
    Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun TAKEUCHI, Satoshi ITADANI, Kazuya HASHIMURA, Masahiro IKURA, Masato HIGASHINO, Tetsuya YASUHIRO, Takeshi NAGAURA
  • Dihydroindolizinone derivative
    Patent number: 10065955
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: September 4, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki Tanaka, Takashi Kondo, Yasuo Hirooka, Taihei Nishiyama, Atsushi Hiramatsu, Tomoyuki Koda, Sho Kouyama
  • PURINONE DERIVATIVE HYDROCHLORIDE
    Publication number: 20180244675
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • IMMUNITY ENHANCING AGENT FOR CANCER BY ALLERGIN-1 ANTAGONIST
    Publication number: 20180244771
    Abstract: A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.
    Type: Application
    Filed: September 2, 2016
    Publication date: August 30, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Hiroshi ARIMA, Takuya SIMBO
  • COMPOUND HAVING EP2 AGONIST ACTIVITY
    Publication number: 20180215747
    Abstract: Provided is an EP2 agonist having excellent safety. A compound represented by general formula (I) (wherein all symbols are as defined in the description), a salt or N-oxide of the compound, or a solvate or prodrug of the compound or the salt or N-oxide has an EP2 agonist activity and is highly safe, and is therefore useful as a medicine, particularly a therapeutic agent for diseases associated with EP2 receptors, such as immune diseases, allergic diseases, neuronal death, dysmenorrhea, premature birth, miscarriage, baldness, ocular diseases, erectile dysfunction, arthritis, lung injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, bone diseases and cartilage injury.
    Type: Application
    Filed: July 22, 2016
    Publication date: August 2, 2018
    Applicant: ONO Pharmaceutical Co., Ltd.
    Inventors: Seiji OGAWA, Toshihide WATANABE, Isamu SUGIMOTO, Kousuke TANI, Kazumi MORIYUKI, Yoshikazu GOTO, Shinsaku YAMANE
  • COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES
    Publication number: 20180194775
    Abstract: Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): wherein all symbols represent the same meanings as those described in the description, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 12, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akiharu ISHIDA, Takeshi MATSUSHITA, Tetsuya SEKIGUCHI, Tatsuya KOMAGATA, Takuya NISHIO
  • Fused imidazole compounds
    Patent number: 10016439
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 10, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji Saito, Masato Higashino, Soichi Kawaharada, Arwel Lewis, Mark Stuart Chambers, Alastair Rae, Kim Louise Hirst, Charles David Hartley
  • BRK INHIBITORY COMPOUND
    Publication number: 20180186800
    Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.
    Type: Application
    Filed: June 21, 2016
    Publication date: July 5, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
  • PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR FIBROMYALGIA
    Publication number: 20180169077
    Abstract: (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] can significantly suppress a decrease of a pain threshold compared to well-known TSPO antagonists, and thus can be an excellent prophylactic and/or therapeutic agent for fibromyalgia, fibromyalgia-associated diseases, and fibromyalgia-associated symptoms.
    Type: Application
    Filed: January 8, 2016
    Publication date: June 21, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seishi KATSUMATA, Katsukuni MITSUI, Yuya EZAKI
  • PURINONE DERIVATIVE
    Publication number: 20180170933
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA